Danaher (NYSE:DHR) Now Covered by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Danaher (NYSE:DHR) in a research note published on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an equal weight rating and a $280.00 price target on the conglomerate’s stock.

A number of other research analysts have also recently commented on DHR. Royal Bank of Canada increased their target price on shares of Danaher from $297.00 to $300.00 and gave the stock an outperform rating in a report on Wednesday, July 24th. Robert W. Baird increased their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an outperform rating in a report on Wednesday, July 24th. Bank of America raised their price objective on shares of Danaher from $270.00 to $275.00 and gave the company a neutral rating in a report on Wednesday, July 24th. Leerink Partners raised their price objective on shares of Danaher from $275.00 to $280.00 and gave the company an outperform rating in a report on Wednesday, July 24th. Finally, Evercore ISI dropped their price objective on shares of Danaher from $266.00 to $260.00 and set an outperform rating for the company in a report on Tuesday, July 2nd. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of Moderate Buy and an average price target of $278.94.

Danaher Price Performance

Shares of DHR opened at $269.31 on Tuesday. The firm has a market capitalization of $199.47 billion, a PE ratio of 45.65, a PEG ratio of 4.62 and a beta of 0.83. The company’s 50-day moving average is $259.76 and its 200-day moving average is $254.94. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the company posted $2.05 earnings per share. Danaher’s revenue was down 2.9% compared to the same quarter last year. Equities analysts forecast that Danaher will post 7.59 EPS for the current year.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock valued at $11,042,433 in the last three months. 11.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Danaher

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in shares of Danaher by 7.4% during the 1st quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock worth $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Wellington Management Group LLP raised its stake in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares during the period. Capital International Investors raised its stake in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after purchasing an additional 1,334,781 shares during the period. Finally, Norges Bank bought a new stake in shares of Danaher during the 4th quarter worth $1,752,382,000. 79.05% of the stock is currently owned by institutional investors.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.